banner
 
bar

program

slides
bar
 
 

The Evolving Landscape of Stroke Prevention in Atrial Fibrillation

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period June 10, 2011 through June 10, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 5 segments totaling 3 hours and 4 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity:

3.0 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the stroke prevention in atrial fibrillation.

Release Date:

June 10, 2011

Expiration Date:

June 10, 2013

Intended Audience:

  • Cardiovascular specialists
  • Prevention-focused cardiologists
  • Thrombosis specialists
  • Anticoagulation specialists
  • Internal medicine specialists
  • Electrophysiology/Heart Rhythm specialists
  • Anticoagulation-focused clinical pharmacists
  • Cardiovascular nursing specialists
  • Neurologists

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by Independent Educational Grants from the Bristol-Myers Squibb/Pfizer Cardiovascular Partnership, Boehringer-Ingelheim, and Ortho-McNeil, Inc., Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil-Janssen Scientific Affairs, LLC

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

SAMUEL Z. GOLDHABER, MD
(Program Chairperson)
Cardiovascular Division
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Consultant: sanofi-aventis, BMS, B-I, EKOS, Merck, Medscape, Eisai, Portola
Grant/Research Support: sanofi-aventis, BMS, B-I, Eisai, J&J, EKOS



ELAINE M. HYLEK, MD, MPH
Associate Professor of Medicine
Department of Medicine
Boston University Medical Center
Boston, MA

Consultant: Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Merck, Pfizerm Portola
Grant/Research Support: Ortho-McNeil – Registry
Executive Steering Committee: Aristotle Trial sponsored by BMS



JEFFREY I. WEITZ, MD, FRCP, FACP
Professor of Medicine and Biochemistry
McMaster University
Director, Henderson Research Center
Canada Research Chair in Thrombosis
Heart and Stroke Foundation
J.F. Mustard Chair in Cardiovascular Research
Hamilton, Ontario, Canada

Consultant: Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Pfizer

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Upon completion of this CME activity, the participants will be able to:

  • Better understand the evidence basis and clinical implications of the evolving, multidimensional landscape for anticoagulation-based management in chronic AF
  • Better understand and be able to deploy evidence-based, risk-specific interventions across the comprehensive (low, moderate, and high risk) spectrum of patient subgroups with AF
  • Learn how to risk stratify patients with atrial fibrillation (AF) in order to determine guideline-consistent and risk-specific treatment based on age, comorbid features, risks and benefits or anticoagulation therapy
  • Learn how to optimize residual stroke risk reduction in AF in low-, moderate- and high risk patient populations, and how to employ the CHADS2, CHADS-VASC, and HAS-BLED risk stratification tools to assist selection of therapies for AF
  • Learn how to systematically analyze late-breaking landmark clinical trials focusing on thromboembolic risk prevention in patients with atrial fibrillation, including those that are intolerant or unable to take warfarin

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved

 
6

 

Key Program Topics Include:

ACC/AHA/ESC Guidelines
ACTIVE-A
anticoagulation
Antiplatelet
Antithrombotic
Apixaban
ARISTOTLE
aspirin
ATHENA
Atrial Fibrillation

Stroke
AVERROES
cardiomyopathy
Cardioversion
CHADS2
CHADS-VASC?
clopidogrel
Dabigatran
Dronedarone

Edoxaban
ESC AF
Factor Xa Inhibitor
HAS-BLED
Hyperthyroidism
Intracerebral Hemorrhage
Myocardial infarction
myocarditis
Pericarditis
Pulmonary embolism

RE-LY Trial
rhythm control
Rivaroxaban
ROCKET-AF
SPAF-I
supraventricular
tachyarrhythmia
Valvular Atrial Fibrillation
VKA